Edgewise Therapeutics
Maureen Franco is an accomplished professional in corporate communications and marketing within the biopharma industry, currently serving as the VP of Corporate Communications at Edgewise Therapeutics since October 2023. Previously, Maureen co-founded and led PRE Commercial as CEO, focusing exclusively on pre-commercial biopharma marketing consulting. Maureen has held significant roles including President at LifeSci Communications, where organizational transformation took place, and CEO at Cambridge BioMarketing, where Maureen drove extensive growth and established the agency as a leader in the rare disease sector. Earlier in Maureen's career, roles included VP positions at Sanofi and Genzyme Therapeutics, where commercial strategies were developed across various divisions. Maureen holds a Bachelor of Science from Boston College and has completed the Strategic Marketing and Management Executive Program at Stanford University Graduate School of Business.
This person is not in any offices
Edgewise Therapeutics
1 followers
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it’s Series B financing round which will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. The company’s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.